DR-164 Functional annotation of the mutated regulatory landscape in glioblastoma
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-164 Functional annotation of the mutated regulatory landscape in glioblastoma
Glioblastoma multiforme (GBM) is the most lethal brain tumour. Mutations in certain genes have been implicated in GBM. However, the …
DR-163 Molecular archaeology of cancer metastases
We aim to apply computational tools to Hartwig Medical Foundation cancer genomes to establish the order in which harmful mutations …
DR-162 Genomic and transcriptomic analysis of e-cadherin mutated breast cancer
There are different types of breast cancer, one is referred to as Invasive Lobular Carcinoma (ILC). ILC accounts for around …
DR-160 Predicting the target-landscape of kinase-inhibitors with explainable 3D convolutional neural networks enables selection of highly personalized therapies
Many tumors show mutations of kinase proteins. When these kinase proteins are mutated, they can provide a catastrophic effect because …
DR-159 “Genomic characterization of metastatic urothelial carcinoma. DR-159 is an extension of DR-031”
See also HMF-DR-031 as this study will be part of DR-031.This project aims to assess the porportion of patients with …
DR-158 Measuring the evolutionary dynamics of positive and negative selection in metastatic cancers
In this project we aim at combining mathematical modelling of tumour evolution with cancer genomic data to measure fundamental evolutionary …
DR-212 Molecular mechanisms of interplay between DNA repair pathways in pancreatic cancer chemo-resistance
Currently, only 20% of pancreatic cancer (PC) patients are qualified for surgery, constituting the only potentially curative treatment available. Despite …
DR-211 Drug response classifier for lung cancer patients
Lung cancer (LC) is the leading cause of cancer mortality. Despite a well-known therapeutic targets and thus a wide spectrum …
DR-210 Genetic causes of resistance to enzalutamide and abiraterone in metastasized castration-resistant prostate cancer patients
Androgen receptor inhibitors (ARi) are frequently used to treat metastatic prostate carcinomas. In this project, we focus on identifying genetic …
DR-209 Studying the association between replication timing and cancer mutational signatures
Mutations are changes in the DNA sequence which can cause cancer. We found that in melanoma and liver cancer different …
DR-208 “Characterisation and in-depth analysis of the genome and clinical correlates of metastatic prostate cancer patients for improved patient stratification. DR-208 is an extension of DR-071”
In this project we aim to use whole genome sequencing data to improve the way we treat patients with prostate …
DR-207 Validation of the WGS analysis pipeline
We have created a local copy of the netflow version of th eHMF WGS pipeline and aim to validate the …
Het aantal WGS- samples dat Hartwig Medical Foundation heeft, is uniek in het onderzoeksveld en groeit snel. Toen we begonnen waren het er 3.500 en dat zijn er nu al meer dan 5.000.